Acting out a word or phrase may help people keep memory of it — a phenomenon called the enactment effect — and this also may hold true for those with poor motor control due to Parkinson’s disease, according to a review study. “Our meta-analysis found that even Parkinson’s disease…
Neuron23 and QIAGEN have joined forces to develop a companion test to predict the response of patients to Neuron23’s experimental treatment for Parkinson’s disease, called NEU-723. “QIAGEN’s blood-based test will help to identify patients with Parkinson’s disease who are likely to respond to Neuron23’s LRRK2 inhibitor,” Nancy Stagliano,…
New trial data suggest that low-dose ketamine — which does not induce anesthesia — may be a potential treatment for levodopa-induced dyskinesia, or involuntary movements, in Parkinson’s disease. “Ketamine was safe [and] well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias,” PharmaTher Holdings, the Canadian-based…
Biotech company Innervace — a spinoff from the University of Pennsylvania — has raised up to $40 million to support the development of its novel regenerative cell therapy platform for Parkinson’s disease. Innervace’s cell therapy platform specifically aims to create implantable tissue to replace the lost neuronal circuits…
New trial data suggest that the combination therapy P2B001 for early Parkinson’s disease may offer effective symptom control with significantly fewer side effects — notably, less daytime sleepiness — than available treatments. The therapy, being developed by the Israeli-based Pharma Two B, could potentially be a first-line,…
Supporters across the nation will make strides against Parkinson’s disease this fall in Moving Day walks — the Parkinson’s Foundation’s signature fundraising effort that also aims to heighten awareness and understanding. Moving Day, a Walk for Parkinson’s events will takes place in 19 cities throughout the U.S.
A non-invasive skin swab test may make a diagnosis of Parkinson’s disease in as few as three minutes, according to a study done at The University of Manchester in the U.K. The test looks at samples of sebum, an oily matter made by glands in the skin, where it can…
Among Parkinson’s disease (PD) patients who participated in a recent survey, 86% reported experiencing daily “off” episodes — when medication wears off and symptoms return — and 56% don’t think their symptoms can improve beyond their current state. Many patients also were not aware of the availability of adjunctive…
Treatment with cannabidiol (CBD) prevented nerve cell death, extended survival, and reduced toxic protein clumps in nematode worm models of Parkinson’s disease, a new study reports. “These findings supported CBD as an anti-parkinsonian drug,” the researchers wrote, adding that “this CBD neuroprotective action might be due to its antioxidative…
A new analysis using machine-learning and sensor data from the Parkinson’s Progression Markers Initiative (PPMI), a digital health research program sponsored by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), successfully distinguished between people with and without Parkinson’s disease, according to a small study led by…
Get regular updates to your inbox.
